Tom Thuren is an accomplished inventor based in Succasunna, NJ (US). He has made significant contributions to the field of medicine, particularly in cardiovascular health. With a total of 4 patents, his work focuses on innovative methods to reduce the risk of cardiovascular events.

Latest Patents

Among his latest patents is a method aimed at reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in patients who have suffered a qualifying CV event. This invention involves an IL-1β binding antibody or a functional fragment thereof, which is designed to prevent or reduce the risk of recurrent cardiovascular events. Another notable patent addresses the treatment of peripheral arterial disease (PAD). This method involves administering an IL-1β binding antibody or functional fragment in doses ranging from about 25 mg to about 300 mg to alleviate the symptoms of PAD.

Career Highlights

Tom Thuren is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on groundbreaking research and development in the pharmaceutical sector. His innovative approaches have the potential to significantly impact patient care and treatment outcomes.

Collaborations

Tom has collaborated with notable colleagues, including Andrew Zalewski and Michael Shetzline. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in healthcare.

Conclusion

Tom Thuren's contributions to medical innovation, particularly in cardiovascular health, highlight his dedication to improving patient outcomes. His patents reflect a commitment to advancing medical science and addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.